United Kingdom· GB-APID-24561811000001109
Lemtrada 12mg/1.2ml concentrate for solution for infusion vials
A alemtuzumab product containing alemtuzumab, registered in United Kingdom by Sanofi. The same ATC class is registered in 11 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Alemtuzumab is registered in 11 of 19 countries.
Countries holding a registration under ATC L04AG06 (alemtuzumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Alemtuzumab · ATC L04AG06
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Alemtuzumab
- Manufacturer
- Sanofi
- Country
- United Kingdom (GB)
- ATC code
- L04AG06
- ATC class
- Alemtuzumab
- Defined daily dose
- 0.13 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 3
- gtin5000283656456
- gtin5000283662181
- gtin5000283660910
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
338 interactions on record for alemtuzumab.
Graded by severity as the source publishes them — 24 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Alemtuzumab · interactions on record
338 records
- 24 severe
- 314 moderate
Most severe, free to view
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Alemtuzumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandLemtradaSanofi Belgium
- CzechiaCAMPATH
- CanadaLEMTRADASANOFI-AVENTIS CANADA INC
- United StatesCampathGenzyme Corporation
- Japanアレムツズマブ（遺伝子組換え）サノフィ
- NetherlandsLEMTRADA 12 mg concentraat voor oplossing voor infusieSanofi Belgium
- PolandLemtradaSanofi Belgium
- SwedenLemtrada 12 mg Koncentrat till infusionsvätska, lösningSanofi Belgium
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lemtrada
- Liechtenstein · Lemtrada
- Norway · Lemtrada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/48bcea08-531d-4ec2-b57f-66dd25114bc1 GET /v1/drugs/48bcea08-531d-4ec2-b57f-66dd25114bc1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "24561811000001109",
"desc": "Lemtrada 12mg/1.2ml concentrate for solution for infusion vials (Sanofi)",
"form": "Solution for infusion",
"vpid": "24565711000001104",
"source": "dmd",
"vtm_id": "774459007",
"strength": "10 mg",
"substance": "Alemtuzumab",
"ingredient": "Alemtuzumab",
"supplier_code": "9190711000001101"
}See everything about alemtuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.